Tumor Suppressor P53: Biology, Signaling Pathways, and Therapeutic Targeting

Overview

Journal Biochim Biophys Acta Rev Cancer

Publisher Elsevier

Specialties Biochemistry
Biophysics
Oncology

Date 2021 May 1

PMID 33932560

Citations 208

Authors

Liz J Hernandez Borrero

Wafik S El-Deiry

Affiliations

Soon will be listed here.

Abstract

TP53 is the most commonly mutated gene in human cancer with over 100,000 literature citations in PubMed. This is a heavily studied pathway in cancer biology and oncology with a history that dates back to 1979 when p53 was discovered. The p53 pathway is a complex cellular stress response network with multiple diverse inputs and downstream outputs relevant to its role as a tumor suppressor pathway. While inroads have been made in understanding the biology and signaling in the p53 pathway, the p53 family, transcriptional readouts, and effects of an array of mutants, the pathway remains challenging in the realm of clinical translation. While the role of mutant p53 as a prognostic factor is recognized, the therapeutic modulation of its wild-type or mutant activities remain a work-in-progress. This review covers current knowledge about the biology, signaling mechanisms in the p53 pathway and summarizes advances in therapeutic development.

Citing Articles

Anastasis and Other Apoptosis-Related Prosurvival Pathways Call for a Paradigm Shift in Oncology: Significance of Deintensification in Treating Solid Tumors.

Mirzayans R Int J Mol Sci. 2025; 26(5).

PMID: 40076508 PMC: 11900100. DOI: 10.3390/ijms26051881.

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.

Maher N, Mouhssine S, Matti B, Alwan A, Gaidano G Cancers (Basel). 2025; 17(5).

PMID: 40075754 PMC: 11899122. DOI: 10.3390/cancers17050907.

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies.

Cardano M, Buscemi G, Zannini L Cells. 2025; 14(5).

PMID: 40072091 PMC: 11898824. DOI: 10.3390/cells14050363.

Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.

Adu-Amankwaah J, You Q, Liu X, Jiang J, Yang D, Liu K MedComm (2020). 2025; 6(3):e70134.

PMID: 40066229 PMC: 11892029. DOI: 10.1002/mco2.70134.

References

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F . MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2011; 19(6):1038-48. PMC: 3354056. DOI: 10.1038/cdd.2011.190. View

Walker K, Levine A . Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A. 1996; 93(26):15335-40. PMC: 26405. DOI: 10.1073/pnas.93.26.15335. View

Sax J, Fei P, Murphy M, Bernhard E, Korsmeyer S, El-Deiry W . BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002; 4(11):842-9. DOI: 10.1038/ncb866. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Hong B, Prabhu V, Zhang S, van den Heuvel A, Dicker D, Kopelovich L . Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res. 2013; 74(4):1153-65. PMC: 4535712. DOI: 10.1158/0008-5472.CAN-13-0955. View

Stewart Z, Leach S, Pietenpol J . p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol. 1998; 19(1):205-15. PMC: 83879. DOI: 10.1128/MCB.19.1.205. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Pavlakis E, Stiewe T . p53's Extended Reach: The Mutant p53 Secretome. Biomolecules. 2020; 10(2). PMC: 7072272. DOI: 10.3390/biom10020307. View

Whitesell L, Sutphin P, An W, Schulte T, Blagosklonny M, Neckers L . Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene. 1997; 14(23):2809-16. DOI: 10.1038/sj.onc.1201120. View

10.

Warnock L, Knox A, Mee T, Raines S, Milner J . Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther. 2008; 7(9):1481-9. DOI: 10.4161/cbt.7.9.6473. View

11.

Chen S, Wu J, Liang Y, Tang Y, Song H, Wu L . Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell. 2020; 39(2):225-239.e8. DOI: 10.1016/j.ccell.2020.11.013. View

12.

Deyoung M, Ellisen L . p63 and p73 in human cancer: defining the network. Oncogene. 2007; 26(36):5169-83. DOI: 10.1038/sj.onc.1210337. View

13.

Shatz M, Menendez D, Resnick M . The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012; 72(16):3948-57. PMC: 3443562. DOI: 10.1158/0008-5472.CAN-11-4134. View

14.

Lukashchuk N, Vousden K . Ubiquitination and degradation of mutant p53. Mol Cell Biol. 2007; 27(23):8284-95. PMC: 2169174. DOI: 10.1128/MCB.00050-07. View

15.

Zhang S, Zhou L, Hong B, van den Heuvel A, Prabhu V, Warfel N . Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res. 2015; 75(18):3842-52. PMC: 4573895. DOI: 10.1158/0008-5472.CAN-13-1079. View

16.

Li T, Santockyte R, Shen R, Tekle E, Wang G, Yang D . Expression of SUMO-2/3 induced senescence through p53- and pRB-mediated pathways. J Biol Chem. 2006; 281(47):36221-7. DOI: 10.1074/jbc.M608236200. View

17.

Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P . Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol. 2013; 42(4):1181-8. DOI: 10.3892/ijo.2013.1818. View

18.

Barlev N, Liu L, Chehab N, Mansfield K, Harris K, Halazonetis T . Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2002; 8(6):1243-54. DOI: 10.1016/s1097-2765(01)00414-2. View

19.

Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C . WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem. 2006; 281(13):8600-6. DOI: 10.1074/jbc.M507611200. View

20.

Lamb P, Crawford L . Characterization of the human p53 gene. Mol Cell Biol. 1986; 6(5):1379-85. PMC: 367661. DOI: 10.1128/mcb.6.5.1379-1385.1986. View